Get the Stockscreener App
12.49
5.81%
-0.77
After Hours:
12.39
-0.10
-0.80%
Turn Therapeutics Inc stock is traded at $12.49, with a volume of 89,951.
It is down -5.81% in the last 24 hours and up +28.37% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
See More
Previous Close:
$13.26
Open:
$13.24
24h Volume:
89,951
Relative Volume:
0.79
Market Cap:
$379.29M
Revenue:
-
Net Income/Loss:
$-1.77M
P/E Ratio:
-83.99
EPS:
-0.1487
Net Cash Flow:
$-1.46M
1W Performance:
-16.40%
1M Performance:
+28.37%
6M Performance:
+266.28%
1Y Performance:
+0.00%
1-Day Range:
$12.30
$13.68
1-Week Range:
$12.06
$15.65
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
12.49 | 379.29M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics (NASDAQ:TTRX) Cut to Sell at Wall Street Zen - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Lucid Cap Mkts - MarketBeat
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating - Investing.com
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating By Investing.com - Investing.com Canada
TTRX: Adaptive trial with pruritus-based enrichment shows strong efficacy in atopic dermatitis - TradingView
Turn Therapeutics at Stifel forum: itch score drives trial design By Investing.com - Investing.com Canada
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to S&P TMI Index - marketscreener.com
Turn Therapeutics' (TTRX) "Sell" Rating Reaffirmed at WBB Securities - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Raised to "Hold" at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - BioSpace
Turn Therapeutics to present at Stifel forum, previewing atopic dermatitis program - TradingView
Turn Therapeutics to Present Atopic Dermatitis Strategy - TipRanks
Former CDC Director Dr. Robert R. Redfield Named Chief Scientific Officer at Turn Therapeutics - The Dermatology Digest
Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer - citybiz
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer - BioSpace
Turn Therapeutics Names Robert Redfield Chief Scientific Officer - TipRanks
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer - Dermatology Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TTRX - Finviz
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Turn Therapeutics (TTRX) Surges 7.34% to $10.38 as Biotech Momentum AcceleratesBreakout Stock Alerts - careplusvn.com
Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX - MarketBeat
Turn (TTRX) Levels: Records a 2.33% Increase to $9.68 in the Current Update; Levels: $9.20 and $10.16 Define the Nearby Reference Levels in the Latest SessionContinuation Pattern Picks - vinanet.vn
Turn (TTRX) Today: Closes 0.84% Lower at $9.46 at the Close; Next Test: the Price Remains Bounded by the Supplied Support and ResistanceAnalyst Upgrade Stocks - vinanet.vn
Turn (TTRX) Quarterly Results: Results Show Limited Variance From Forecasts under the Current Snapshot; Closing Move: The Share Price Sheds 0.84% on the DayBanking Earnings Report - careplusvn.com
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordFibonacci Entry Signals - vinanet.vn
Turn (TTRX) Results Breakdown: Available Metrics Are Broadly in Line for the Current Session; After Earnings: The Stock Ends Down 2.85% at the CloseGuidance Accuracy Score - vinanet.vn
Turn (TTRX) Close: Ends Lower by 0.20% at $9.80 on the Day; Current Setup: Traders Can Monitor the $9.31-$10.29 Range in Latest TradingWedge Breakout - vinanet.vn
GX-03 Selectively Reduces Key Drivers of Skin Inflammation, Itch - The Dermatology Digest
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model - Dermatology Times
Turn Therapeutics publishes study on GX-03 skin therapy - Investing.com
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com India
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire
Turn Therapeutics Issues 579,664 Shares in Cashless Warrant Exercise - Minichart
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance - TipRanks
Turn Therapeutics Completes Cashless Exercise of GEM Warrant, Issues 579,664 Shares - Kalkine Media
Turn Therapeutics Raises $1.35 Million in Private Placement - Minichart
Turn Therapeutics Secures $1.35 Million Through Private Stock Placement - Kalkine Media
Turn Therapeutics Raises $1.35M Through Private Placement - TipRanks
Turn Therapeutics (TTRX) Rallies 3.55% to $9.91, Approaching Key $10.41 ResistanceBeta Neutral Pair - vinanet.vn
Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16 - Moomoo
Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5%Time to Sell? - MarketBeat
Turn Therapeutics Inc. announced that it expects to receive $1.35 million in funding - marketscreener.com
Turn Therapeutics (TTRX) Falls 5.6% to $9.95 as Support at $9.45 Comes into FocusRetracement Entry - vinanet.vn
Turn Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Long-Term Debt - Kalkine Media
Form 8K Turn Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Turn Therapeutics (NASDAQ: TTRX) posts larger loss, adds debt and warns on going concern - Stock Titan
Turn Therapeutics Q2 net loss per share widens on higher R&D costs - TradingView
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Turn Therapeutics Inc Stock (TTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):